Embecta Corp.

NasdaqGS EMBC

Embecta Corp. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024

Embecta Corp. Revenue Per Share is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Embecta Corp. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 19.57, a -0.50% change year over year.
Embecta Corp. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 19.67, a -4.77% change year over year.
Embecta Corp. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 20.65.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqGS: EMBC

Embecta Corp.

CEO	Mr. Devdatt Kurdikar
IPO Date	March 22, 2022
Location	United States
Headquarters	300 Kimball Drive
Employees	2,200
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Key trends

Past 5 years